| Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
|
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Advances and challenges in the treatment of myelodysplastic syndromes |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Advancing drug development in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Alcohol use is not a significant contributor to myelodysplastic syndromes |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
